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Progeroid disorders overlappingwith De Barsy syndrome (DBS) are collectively denoted as autosomal-recessive cutis laxa type 3 (ARCL3).
They are caused by biallelic mutations in PYCR1 or ALDH18A1, encoding pyrroline-5-carboxylate reductase 1 and pyrroline-5-carbox-
ylate synthase (P5CS), respectively, which both operate in themitochondrial proline cycle.We report here on eight unrelated individuals
born to non-consanguineous families clinically diagnosed with DBS or wrinkly skin syndrome.We found three heterozygous mutations
inALDH18A1 leading to amino acid substitutions of the same highly conserved residue, Arg138 in P5CS. A de novo originwas confirmed
in all six probands for whom parental DNA was available. Using fibroblasts from affected individuals and heterologous overexpression,
we found that the P5CS-p.Arg138Trp protein was stable and able to interact with wild-type P5CS but showed an altered sub-mitochon-
drial distribution. A reduced size upon native gel electrophoresis indicated an alteration of the structure or composition of P5CS mutant
complex. Furthermore, we found that themutant cells had a reduced P5CS enzymatic activity leading to a delayed proline accumulation.
In summary, recurrent de novomutations, affecting the highly conserved residue Arg138 of P5CS, cause an autosomal-dominant form of
cutis laxa with progeroid features. Our data provide insights into the etiology of cutis laxa diseases and will have immediate impact on
diagnostics and genetic counseling.Syndromes with cutis laxa (CL) exhibit autosomal-domi-
nant, autosomal-recessive, and X-linked modes of inheri-
tance.1 The currently known autosomal-dominant forms
are exclusively due tomutations in genes encoding proteins
of the extracellular matrix (ECM). Beside the cutis laxa
phenotype, affected individuals with mutations in ELN
(MIM: 130160), encoding elastin (ADCL1 [MIM: 123700]),
show severe cardiovascular and pulmonary symptoms.2,3
Additionally, mutations in FBLN5 (MIM: 604580) (ADCL2
[MIM: 614434]) were shown to cause an overlapping condi-
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The AmericanThe autosomal-recessive forms of cutis laxa are clini-
cally and genetically most variable.1,5 They can be subdi-
vided into three distinct groups based on the clinical
presentation and the localization of the affected gene
products. ARCL type 1 (ARCL1 [MIM: 2191009]) is the
most severe form with manifestations in the cardiovas-
cular, pulmonary, genitourinary, and gastrointestinal sys-
tems. They are due to mutations in EFEMP2 (MIM:
604633), FBLN5, or LTBP4 (MIM: 604710) encoding com-
ponents or modifiers of the ECM.6–9 In one case, biallelic
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form of ARCL, which mainly shows arterial tortuosity and
only mild cutis laxa, is due to mutations affecting the
facilitated glucose transporter GLUT10 (SLC2A10 [MIM:
606145]).11,12
Autosomal-recessive cutis laxa type 2A (ARCL2A
[MIM: 219200]) is caused by mutations in ATP6V0A2
(MIM: 611716), which encodes the a2 subunit of the
V-type Hþ-ATPase mainly localized to the Golgi apparatus.
ARCL2A is further characterized by a typical facial Gestalt,
skeletal involvement, and variable intellectual disability.
The presence of a glycosylation defect classifies this disor-
der also as a congenital disorder of glycosylation.13–15
Macrocephaly, alopecia, cutis laxa, and scoliosis (MACS
[MIM: 613075]) syndrome is another disorder belonging
to the ARCL disease spectrum, which is due to mutations
in RIN2 (MIM: 600222), encoding an effector of the small
GTPase Rab5. A mild hypoglycosylation of serum proteins
can also be observed in RIN2-related cutis laxa.16,17 Gero-
dermia osteodysplastica (GO [MIM: 231070]) is caused by
mutations in GORAB (MIM: 607983) encoding an effector
of the small GTPases RAB6 andARF5.18 Individuals affected
by GO have a progeroid aspect, pronounced osteoporosis
with fractures in early infancy, and usually no intellectual
disability.19,20 ARCL2B (MIM: 612940) partially resembles
GO but can be distinguished by a typical facial Gestalt
and intellectual disability in most of the affected individ-
uals. It is caused by mutations in PYCR1 (MIM: 179035)
encoding pyrroline-5-carboxylate reductase 1, an enzyme
involved in the de novo synthesis of proline from pyrro-
line-5-carboxylate (P5C) residing in mitochondria.21–25
ARCL type 3 (ARCL3A [MIM: 219150]; ARCL3B
[MIM: 614438]) comprises De Barsy syndrome,26,27 which
can be regarded as an extreme form of the clinical spectrum
of ARCL2B with more pronounced progeroid appearance,
cataract or corneal clouding, and profound intellectual
disability.MostDeBarsy-like (ARCL3)-affected persons carry
mutations in PYCR1.21,28 Interestingly, mutations in PYCR2
(MIM: 616406) encoding the closely related enzyme pyrro-
line-5-carboxylate reductase 2 cause a phenotype with
microcephaly and hypomyelination, but without skin
manifestations.29 Mutations in ALDH18A1 (MIM: 138250),
which encodes the mitochondrial enzyme pyrroline-5-
carboxylate synthase (P5CS) responsible for the conversion
of glutamic acid to P5C, have been found in the most
severely affected ARCL3 individuals.25,30–35 PYCR1/2 and
the enzyme proline dehydrogenase (PRODH) catalyzing
the reverse reaction are key components of the proline cycle,
which shuttles redox equivalents in and out mitochon-
dria.36 Furthermore, this pathway is tightly connected to
the urea cycle via ornithine aminotransferase (OAT) and to
the TCA cycle via glutamate dehydrogenase (GLDH).37
P5CS and its counterpart pyrroline-5-carboxylate dehydro-
genase (P5CDH) can also be regarded as integral parts of
this proline cycle, because transporters for both end prod-
ucts, proline and glutamate, are present in mitochondria.
In thepresent studywedescribe eight affected individuals
originating from Jordan, Finland, the Netherlands,Mexico,484 The American Journal of Human Genetics 97, 483–492, SeptembArab Emirates, and the United States presenting with a pro-
geroid, De Barsy-like cutis laxa phenotype. The family his-
tories contained no information on other subjects with
cutis laxa or other connective tissue disorders, miscarriage,
early abortion, or consanguinity (Table 1, Figure 1A). All
affected individuals showed a typical facial Gestalt with a
triangular face, a prominent and broad forehead, cataracts
or corneal clouding, and prominent low-set ears
(Figure 1B). Furthermore, all probands presented with pre-
natal, and seven also with postnatal, growth restriction.
All individuals had lax and thin skin with visible veins
and joint hyperlaxity, six presented with cataracts, five
with adducted thumbs, and fourwith cranial vessel tortuos-
ity (Figure 1B, Table 1). Psychomotor development was de-
layed in all probands. Joint hyperlaxity andmuscle hypoto-
nia might have contributed to the motor delay as noted in
thepreviouslypublishedcase report for theaffected individ-
ual 2-II:1.38 Furthermore, at least three probands presented
with brisk peripheral reflexes. In addition, proband 3-II:1
was diagnosed with an autism spectrum disorder and in
the affected individuals 2-II:1 and 3-II:1, a foramen mag-
num stenosis was observed. Based on the clinical features,
the initial diagnosis of De Barsy syndrome was made in
all affected individuals, except1-II:4, 4-II:1, and7-II:1 (Table
1). Because of a clinical overlap with progeroid Ehlers-Dan-
los syndrome, collagen type 1 and 3 production was as-
sessed in proband 2-II:1 and showed reduced levels for the
age range.38 In individuals 3-II:1 and 4-II:1, plasma amino
acid profiling revealed no abnormalities. However, in the
affected individual 7-II:1, the plasma amino acid levels of
ornithine, arginine, and proline were decreased and in pro-
band 8-II:2, ornithine, citrulline, and proline were reduced.
To identify themolecular genetic basis of the observedDe
Barsy-likephenotype,we investigated thegenesALDH18A1
(GenBank: NM_002860.3) and PYCR1 (GenBank: NM_
001282280.1) by conventional Sanger sequencing in fam-
ilies 1–4 and 6–8 as described previously.31,34 In proband
5-II:3 we used a gene panel approach capturing the most
relevant genes linked to connective tissue disorders
(Figure S1A). In all affected individuals, sequencing of
PYCR1, the most frequently affected gene in ARCL3, re-
vealed no pathogenic sequence alteration.13 However, in
the affected individuals 1-II:4, 2-II:1, and 3-II:1, a heterozy-
gous change c.412C>T (p.Arg138Trp) and in 4-II:1 and
5-II:3 the transitionc.413G>T (p.Arg138Leu) inALDH18A1
were found (Figure 2A, Table 1). In the affected individuals
6-II:1, 7-II:1, and 8-II:2, we found the heterozygous substi-
tution c.413G>A (p.Arg138Gln) (Figure 2A, Table 1). In
none of the case subjects was a second mutation or patho-
genic rare variant in the ALDH18A1 coding region detect-
able. Next, we excluded an additional exonic deletion in
the ALDH18A1 locus in individuals 2-II:1, 5-II:3, and
6-II:1 by quantitative PCR and by cDNA expression analysis
in probands 1-II:4 and 3-II:1 (data not shown). Because no
second hit in ALDH18A1 was detectable, we sequenced
DNA from the parents of families 1–3, 5, 7, and 8 to investi-
gate whether themutationswere inherited. To our surprise,er 3, 2015
Table 1. Summary of Clinical and Molecular Findings in Individuals with De Novo ALDH18A1 Mutations
Family 1 Family 2 Family 3 Family 4 Family 5 Family 6 Family 7 Family 8 Freq.
Clinical Findings
Origin Jordan Finland Netherlands USA Mexico UAE USA USA
Age at Last Evaluation 2.5 years 2.9 years 2 years 6 years 4 years 13 years 3 years 3 years
IUGR þ þ þ þ þ þ þ þ 100%
Postnatal growth delay þ þ  þ þ þ þ þ 88%
Dysmorphic features  þ þ þ þ þ þ þ 88%
Lax, wrinkled skin þ þ þ þ þ þ þ þ 100%
Thin, translucent skin þ þ þ þ þ þ þ þ 100%
Joint hyperlaxity þ þ þ þ þ þ þ þ 100%
Hernias þ þ þ þ  þ  þ 100%
Hip dislocation ND þ   þ þ þ þ 71%
Adducted thumb þ þ   þ þ  þ 63%
Club foot  þ   þ þ   38%
Abnormal spine
curvature
 þ   þ þ   38%
Osteopenia  þ   þ  ND þ 43%
Late fontanel closure  þ þ  þ ND  þ 50%
Wormian bones ND þ þ      29%
Microcephaly þ   þ þ þ þ  63%
Brain anomalies  þ    ND   14%
Cranial vessel tortuosity   þ þ   þ þ 50%
Psychomotor retardation þ þ þ þ þ þ þ þ 100%
Autism ND ND þ  ND ND ND  33%
Feeding difficulties  þ þ þ ND ND þ þ 83%
Hypotonia þ þ þ þ þ ND þ þ 100%
Brisk reflexes  þ þ ND þ ND   50%
Cataract  þ þ þ þ þ þ þ 88%
Strabismus   þ     þ 25%
Additional clinical
findings
 foramen
magnum
stenosis
foramen magnum
stenosis, shallow
sella turcica
os odontoideum,
disharmonic
bone age
   
Plasma amino acid
levels
ND ND normal normal ND ND ornithine Y,
arginine Y,
proline Y
ornithine Y,
citrulline Y,
proline Y
Initial diagnosis WSS DBS DBS connective
tissue disorder
DBS DBS cutis laxa DBS
Molecular Findings
cDNA c.412C>T c.412C>T c.412C>T c.413G>T c.413G>T c.413G>A c.413G>A c.413G>A
Parental origin paternal ND paternal ND ND ND paternal ND
Protein p.Arg138Trp p.Arg138Trp p.Arg138Trp p.Arg138Leu p.Arg138Leu p.Arg138Gln p.Arg138Gln p.Arg138Gln
MutationTaster score 0.9999 (DC) 0.9999 (DC) 0.9999 (DC)
PolyPhen2 score 1.000 (PD) 1.000 (PD) 1.000 (PD)
SIFT score 0 (D) 0.04 (D) 0.04 (D)
Abbreviations and symbols are as follows:þ, present;, absent; ND, not determined; DC, disease causing; PD, probably damaging; D, damaging; Freq, frequency
of feature.
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Figure 1. Pedigrees and Clinical Pheno-
type of Eight De Barsy-like Affected Indi-
viduals
(A) Pedigrees of families 1–8 with De Barsy-
like affected individuals.
(B) Clinical phenotype of probands 1-II:4,
3-II:1, 4-II:1, 5-II:3, and 6-II:1 at various
ages between 5 months and 13 years.
Ages are given in the lower right corner.
Note triangular face, wrinkly and translu-
cent skin (especially visible in 2-II:2 and
5-II:3), adducted thumbs, and abnormal
spine curvature in the oldest proband
6-II:1. Muscular hypotonia is visible in
proband 4-II:1. Written consent for publi-
cation of photographs from affected indi-
viduals was given by the probands’ legal
representatives.in all six families analyzed, a de novo occurrence of themu-
tationwas proven.Unfortunately, noDNAwas available for
the parents from family 6 and only thematernal DNA from
family 4 was available. In three case subjects, nearby SNPs
allowed us to elucidate a paternal origin of the mutated
allele (Figures S1B and S1C).Mutations affecting the residue
Arg138 have not been described previously and are not
mentioned in the ExAC, EVS, or the 1000 Genomes Project
datasets. These mutations were predicted to be patho-
genic according to MutationTaster, PolyPhen-2, and SIFT
(Table 1). The residue Arg138 is phylogenetically highly
conserved among all eukaryotes (Figure 2B). However, a
19 amino acid stretch containing Arg138 is absent in the
orthologous E. coli enzyme g-glutamyl kinase.
To further investigate the molecular basis of this disease,
we documented that formation of the P5CS proteinwas not
significantly reduced in skin fibroblasts bearing the hetero-
zygous p.Arg138Trp substitution (Figures 3A and S2A). The
levels of PYCR1 were unaltered or slightly higher. Because
the protein was stable, a possible explanation for the path-
ogenic effect would be an altered targeting of the mutant
P5CS protein. Superresolution microscopy revealed that
P5CS co-localizes significantly more with the outer mito-
chondrial membrane marker TOM20 in P5CS mutant cells
than in control cells, as shown by the Pearson’s correlation
coefficients (Figure 3B). Furthermore, in fibroblasts derived486 The American Journal of Human Genetics 97, 483–492, September 3, 2015from affected individuals, P5CS
showed ribbon-like structures whereas
in control cells more discrete puncta
were visible (Figure 3C). To selectively
assess the subcellular localization of
P5CS-p.Arg138Trp, we created cell
lines stably producing P5CS-WT and
P5CS-p.Arg138Trp using the pLXIN
vector system (Clontech) according
to manufacturer instructions. Again,
a mitochondrial localization was
visible, and the mutant protein P5CS-
p.Arg138Trp-V5 showed a more even
distribution within themitochondrialnetwork and less accumulation in puncta when compared
to V5-tagged wild-type P5CS (Figure S2B). We suspected
that the altered localization of the mutant P5CS-
p.Arg138Trp enzyme could impact its function and have
dominant effects on the wild-type P5CS.
It is known that the prokaryotic ortholog of the N-termi-
nal portion of the bifunctional P5CS enzyme, g-glutamyl
kinase, is a dimer of dimers and a similar structure is
also assumed for mammalian P5CS.39,40 In order to know
whether substitutions of Arg138 alter the protein interac-
tion profile of P5CS, we performed co-immunoprecipita-
tion with transfected HEK293T cells and found that the
substitutions did not interfere with the ability to bind
P5CS-WT molecules (Figure 4A). Furthermore, we investi-
gated the endogenous protein complex containing P5CS
in fibroblast lysates from affected and control individuals
by using native-PAGE followed by immunoblot analysis.
In control cells, the total size of the P5CS-containing pro-
tein complex was approximately 440 kDa, which is larger
than the theoretical 349 kDa for a P5CS homotetramer.
Compared to that, the size of the complex containing
the P5CS-p.Arg138Trp mutant protein in proband-derived
fibroblasts was reproducibly smaller (about 410 kDa)
(Figure 4B). The two most obvious explanations for the
apparent mass of the P5CS complex would be binding of
additional proteins other than P5CS or posttranslational
Figure 2. Heterozygous De Novo Muta-
tions Affecting Arg138, a Highly
Conserved Residue of P5CS
(A) Sequence traces of ALDH18A1 exon 4
from affected individuals and parents
demonstrating a de novo origin of the
c.412C>T, c.413G>T, and c.413G>A
mutations leading to the amino acid sub-
stitutions p.Arg138Trp, p.Arg138Leu, and
p.Arg138Gln, respectively, in P5CS. Con-
sents for molecular studies were obtained
from all legal representatives of the affected
infants. The Charite´-Universitaetsmedizin
Berlin ethics committee and the Institu-
tional Review Board from the National
University of Singapore approved the
study.
(B) Alignment of P5CS protein sequence
from different species around mutated
human residue Arg138. Shading indicates
degree of conservation. Note that E. coli
does not contain any residue orthologous
to Arg138, although it is conserved in all
other species.
(C) Domains and alterations of the P5CS
protein. The substitutions described in
this study are given in red; all known
alterations are given in black below the
drawing. Cys612 is a catalytically impor-
tant residue. Abbreviations are as follows:
MTS, mitochondrial targeting sequence;
GK, g-glutamyl kinase; GPR, glutamyl-
phosphate reductase.modifications of P5CS itself. The reduced size of the
mutant P5CS protein might indicate that one of these
mechanisms or the whole 3D conformation is disturbed.
Therefore, we asked whether this substitution interferes
with the catalytic function of the enzyme. To answer this
question, we chose to quantify the flux through the gluta-
mate-proline pathway.We provided 13C5
15N-labeled gluta-
mic acid to the cells and after 6 and 12 hr we determined
the amount of 13C5
15N-labeled proline by mass spectrom-
etry as previously described by Bicknell et al. (Figure 5A).30
In the controls we found similar amounts of labeled
proline at the indicated time points, whereas in the
P5CS-deficient cell line and the fibroblast lines bearing
the heterozygous p.Arg138Trp substitution a reduced pro-
line accumulation was detectable (Figure 5B).
In 1968 de Barsy described an affected individual with
profound intellectual disability, choreoathetoid move-
ments, clouded corneas, and a progeroid appearance.26
More recently, affected individuals with a very similar
phenotype were described to harbor biallelic mutations
in ALDH18A1 (ARCL3A) or in PYCR1 (ARCL3B). Only 13
affected individuals from 7 unrelated families carrying
biallelic ALDH18A1 mutations have been described so
far.31 The present study shows de novo heterozygous
mutations in ALDH18A1 affecting the highly conservedThe American Journal of Human Genamino acid Arg138 of P5CS as the
cause of a similar but milder progeroid
cutis laxa phenotype, which hasimportant impact for diagnostics and genetic counseling.
All probands showed cataract or corneal clouding, thin
skin with visible veins and wrinkles, moderate intellectual
disability, clenched fingers, and pre- and postnatal growth
retardation. Though this phenotype is reminiscent of the
milder PYCR1-related cutis laxa phenotype, cataract and/
or corneal clouding seem to be distinctive.21 The neurolog-
ical phenotype of our probands is further characterized by
a combination of muscular hypotonia with brisk muscle
reflexes, reminiscent of disorders affecting the upper moto-
neuron like the spastic paraplegias (SPGs). Indeed, hetero-
zygous inherited mutations in different ALDH18A1 exons
have recently been shown to be causative for SPG9 (MIM:
601162) with an onset from the first to the fourth decade
of life.41 These data further increase the plausibility of a
pathogenic effect of heterozygous P5CS variants and
expand the disease spectrum caused by ALDH18A1 muta-
tions. Consequently, the phenotype with a pre- or
neonatal onset described here lies within the clinical spec-
trum of disorders caused by biallelic mutations either in
PYCR1 or ALDH18A1. We propose to call this disease entity
autosomal-dominant cutis laxa with progeroid features
(ALDH18A1-ADCL) to distinguish it from ELN-ADCL and
FBLN5-ADCL. It should be noted that the parents of the
sporadic case initially described by de Barsy et al. were ofetics 97, 483–492, September 3, 2015 487
Figure 3. Normal Levels and Altered
Mitochondrial Targeting of the P5CS-
p.Arg138Trp Protein
(A) No reduction in P5CS or PYCR1 levels
in skin fibroblasts from proband (P)
1-II:4 compared to fibroblasts harboring
the homozygous PYCR1 substitution
p.Lys215_Asp319del cultivated in DMEM
with 4.5 g/l glucose supplemented with
10% FCS, 1% ultraglutamine, and 1% peni-
cillin/streptomycin at 37C in a 5% CO2
atmosphere.28 For immunoblot, cells were
lysed with modified RIPA (50 mM Tris-
HCL, 1% NP40, 0.25% Na-deoxycholat,
150 mM NaCl, 1 mM EDTA þ Complete
proteinase inhibitor cocktail [Roche]) and
protein concentrations were determined
with the BCA-Kit (Pierce). A total amount
of 20 mg protein was separated on a SDS-
PAGE gel and proteins were transferred to
nitrocellulose membranes. Membranes
were blocked for 30 min at RT and pri-
mary antibodies (P5CS, Novus; GAPDH,
Ambion; PYCR1, PTG) were incubated
overnight at 4C. After washing, the corre-
sponding HRP-conjugated secondary anti-
bodies were incubated for 1 hr at RT. Bands
were visualized with ECL reagent (Perki-
nElmer). All blots were performed at least
three times using different cell lysates.
(B) For each sample, five individual cells
were imaged and the Pearson’s correlation
coefficient calculatedwith the Coloc2 tools
in FIJI.46 The graph shows that the co-
localization between TOM20 and P5CS is
3.5- to 5.5-fold higher in cells from affected
individuals compared to controls. Error in-
dicates 1 SEM; n.s. indicates not signifi-
cant; ***p < 0.001.
(C) Mitochondrial localization of P5CS
(green) complexes containing P5CS-
p.Arg138Trp in comparison to the mito-
chondrial outer membrane marker
TOM20 (red) as determined by superreso-
lution microscopy. After fixation and
permeabilization, primary antibodies were
incubated overnight at 4C. Secondary an-
tibodies labeled with either 488 or 568
Alexa Fluor dyes (Life technologies) were
incubated 1 hr at room temperature. Slides were mounted in VECTASHIELD H-1000 (Vector Laboratories). Superresolution images
were acquired with a DeltaVision OMX v4 Blaze (GE Healthcare). The mutated protein forms smaller protein accumulations and is
more evenly distributed throughout the mitochondrial network. Scale bars represent 5 mm.different nationalities.26 Although this does not exclude a
coincidental inheritance of two rare loss-of-functionmuta-
tions in ALDH18A1 or PYCR1, our data open the possibility
that also in this case a de novo ALDH18A1mutationmight
have been causative. Furthermore, Martinelli et al. re-
ported on a case carrying the de novo p.Gly93Arg
(c.277G>A) substitution in combination with the poly-
morphism p.Thr299Ile (c.896C>T).33 Interestingly, this
proband seems more severely affected because he had
cortical atrophy, thin corpus callosum, clonic seizures,
and metabolic abnormalities with hyperammonemia and
low plasma citrulline levels. Only in a subgroup of reces-
sive cases are alterations of plasma amino acids pre-
sent.33,42 The absence of such metabolic features does488 The American Journal of Human Genetics 97, 483–492, Septembnot rule out the diagnosis of ALDH18A1-related cutis
laxa, but when present they are a strong indication for
P5CS deficiency as in our probands 7-II and 8-II:2.
Most ALDH18A1-related ARCL mutations cluster in the
C-terminal region of P5CS between amino acids 601 and
784, which lies within the g-glutamyl phosphate reductase
domain (Figure 2C). Only two mutations residing in
the P5CS g-glutamyl-kinase domain have already been
described: a homozygous p.Arg84Gln substitution and,
as mentioned above, the heterozygous de novo substitu-
tion p.Gly93Arg.33,42 In contrast to biallelic ALDH18A1
mutations, the de novo mutations described here are
unlikely to completely destroy P5CS enzymatic function.
This is further supported by the strongly reduced prolineer 3, 2015
Figure 4. Preserved Interaction of P5CS-p.Arg138Trp and
Altered Size of Protein Complex
(A) Co-immunoprecipitation of PC-tagged P5CS and P5CS-
p.Arg138Trp with HA-tagged P5CS and P5CS-p.Arg138Trp.
30-tagged human ALDH18A1 wild-type and c.412C>T mutant
ORFs, cloned into pCS2þ between the BamHI and XhoI restriction
site, were expressed in HEK293 cells after transient transfection
with a NEPA21 super Eletroporator (NEPAGENE). Unrelated pro-
teins ASUN-PC and ELMO-PC served as negative controls. Proteins
were extracted with lysis buffer (50 mM Tris [pH 7.5], 150 mM
NaCl, 0.1% Nonidet P-40, 0.05% deoxycholate, 1 mM CaCl2)
supplemented with protease inhibitor cocktail (Roche). Protein
C-tagged proteins were co-immunoprecipitated on Anti-Protein
C Affinity Matrix (Roche) during 5 hr at 4C together with HA-
tagged proteins overnight at 4C. Bound proteins were eluted
from the beads via a wash buffer (20 mM Tris [pH 7.5], 0.5 M
NaCl, 1 mM CaCl2). Electrophoresis was carried out in reducing
loading buffer and analyzed by immunoblotting with indicated
antibodies. Immunoblotting of cell lysates with antibodies against
PC and HA revealed comparable expression of all tagged proteins.
(B) Native gel electrophoresis of P5CS-containing protein com-
plexes isolated from fibroblasts from control individuals, probands
(P) 2-II:1 and 3-II:1, and fibroblasts from an individual with the
homozygous P5CS substitution p.Val601Glyfs*24.31 Cells were
lysed with modified RIPA (50 mM Tris-HCl, 1% NP40, 0.25%
The Americanaccumulation in the cell lines harboring p.Arg138Trp in
comparison to complete P5CS deficiency. P5CS, which
catalyzes the first step of proline biosynthesis, is assumed
to be a dimer of dimers.39 Statistically, 6.25% of all formed
tetramers can be predicted to still consist of wild-type
P5CS molecules if only one allele carries a mutation.
Furthermore, it is possible that tetramers containing both
wild-type and mutated subunits might still retain some
function, especially if the mutated protein is stable and
able to interact with the wild-type form, as demonstrated
in our study for P5CS-p.Arg138Trp. We believe that this
finding is crucial to explain a dominant-negative effect
because in the absence of binding, we would end up
with 50% of wild-type P5CS complexes, which are obvi-
ously sufficient for a healthy development.
P5CS targets to mitochondria through a N-terminal
mitochondrial targeting signal (MTS).39 Overexpressed
P5CS-p.Arg138Trp also co-localized with mitochondrial
markers, but whereas overexpressed P5CS-WT formed
large aggregates in vicinity to mitochondria, the mutated
protein was more evenly dispersed within the mitochon-
drial network. An important difference between intrinsic
P5CS protein complexes isolated from fibroblasts from
control and affected individuals was a size reduction
detectable after native-PAGE indicating either loss of an
interaction partner, an altered 3D conformation due to
the altered charge, or an abnormal modification of the
P5CS-p.Arg138Trp-containing complexes. The size of the
wild-type complex was approximately 440 kDa. If P5CS
is a tetramer, the theoretical size of this complex would
be 349 kDa, which would leave room for additional bind-
ing partners with a total mass of 90 kDa.39 On the other
hand, apart from P5CS itself, eight potential binding part-
ners are mentioned in the IntAct database.43 Of those only
ICT1, a 22 kDa subunit of the mitochondrial ribosome, re-
sides in the correct organelle. Further research is needed
to determine whether there are relevant P5CS interaction
partners. Interestingly, three P5CS lysine residues have
been shown to undergo succinylation.44 An altered lysine
succinylation could influence the folding state of the P5CS
monomers and thereby the migration of the protein com-
plex in the native-PAGE gel. An alternative explanation
would be an altered proteolytic cleavage of the P5CS pro-
tein. An obvious candidate would be the predicted MTS.
In proteins of the mitochondrial intermembrane space
like P5CS, the MTS can get cleaved by the inner membraneNa-deoxycholat, 150 mMNaCl, 1 mM EDTA þ Complete protein-
ase inhibitor cocktail [Roche]) and protein concentrations were
determined with the BCA-Kit (Pierce). A total amount of 5 mg pro-
tein was separated on a native-PAGE gel. Proteins were transferred
to a nitrocellulose membrane and incubated with a P5CS antibody
(Novus) to visualize the native protein complex. In control cells, a
complex of an approximate size of 440 kDa was detected, which
appeared smaller in lysates from p.Arg138Trp-expressing fibro-
blasts. The immunoblots below show identical lysates run in
SDS-PAGE under denaturing conditions showing comparable
loading by P5CS and GAPDH detection.
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Figure 5. Reduced Proline Accumulation in Fibroblasts from
Affected IndividualsHarboring theP5CS-p.Arg138TrpSubstitution
(A) Overview of the design of the metabolic labeling experiment
and the underlying biochemical pathway. Confluent skin fibro-
blasts derived from healthy controls, the probands (P) 1-II:4 and
3-II:1, and an individual with a homozygous P5CS p.Val601-
Glyfs*24 substitution were washed with HBSS (Hanks’ Balanced
Salt Solution) and incubated with medium containing 2 mM 13
C5
15N glutamic acid (Silantes) for 6 and 12 hr, respectively. After
uptake of the isotopic glutamic acid, the cells (dotted oval) metab-
olized this substrate and generated 13C5
15N proline via the indi-
cated pathway. The cells were again washed and collected in
100 ml HBSS. Subsequently, the metabolites were extracted and
analyzed via a targeted LC-MS/MS approach.47
(B) 13C5
15N proline levels relative to Ctrl 1 6 hr values. The result-
ing ratios are given with a log2 scale. Note clearly reduced effi-
ciency of 13C5
15N proline accumulation in cells harboring biallelic
or monoallelic ALDH18A1 mutations.peptidase (IMP).45 Further experiments will be needed
to specify by which mechanism P5CS is targeted and
processed.
Taken together, we have shown here that heterozygous
P5CS de novo mutations affecting the residue Arg138
lead to subtle changes in the behavior of the P5CS protein
complex and its enzymatic function. Our results clearly
show that besides mutations that affect components of
the ECM, mutations affecting the mitochondrial protein
P5CS can cause a form of autosomal-dominant cutis laxa
with progeroid features resembling De Barsy syndrome.Supplemental Data
Supplemental Data include two figures and can be found with
this article online at http://dx.doi.org/10.1016/j.ajhg.2015.08.
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